RayKnowChina Research Map
Shortlist0

RecruitingMoyamoya diseaseN/A

Registered title, quoted from ClinicalTrials.gov

Efficacy and Safety of Ischemic Preconditioning Therapy Versus Optimal Medical Therapy in Reducing the Recurrence of Ischemic Events in Symptomatic Moyamoya Disease

An open trial on moyamoya disease, registered on ClinicalTrials.gov. Led by Beijing Tiantan Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorBeijing Tiantan Hospital首都医科大学附属北京天坛医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07889531, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 2

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (2 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. After clinical evaluation, non-surgical treatment strategies such as drug therapy and risk factor management are planned to be adopted currently, and the patient is not planned to undergo cerebral blood flow revascularization within 6 months after randomization during screening;

    Inclusion criterion 4

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07889531, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • The patient is aged between 18 and 70 years old;
  • There is evidence from MRA, CTA or DSA, and the patient is professionally diagnosed with moyamoya disease or moyamoya syndrome;
  • The patient has ischemic symptoms related to moyamoya vasculopathy, including transient ischemic attack (TIA) and cerebral infarction (limb weakness, hemiplegia, paresthesia, speech disorder, etc. The symptoms may recur in the unilateral limb, or progress to bilateral attacks or alternating bilateral attacks);
  • After clinical evaluation, non-surgical treatment strategies such as drug therapy and risk factor management are planned to be adopted currently, and the patient is not planned to undergo cerebral blood flow revascularization within 6 months after randomization during screening;
  • The patient has signed the informed consent form.

Exclusion Criteria:

  • History of intracranial hemorrhage (such as subarachnoid hemorrhage, cerebral parenchymal hemorrhage and intraventricular hemorrhage) and other cerebrovascular diseases (such as intracranial aneurysm, cerebral arteriovenous malformation, arteriovenous fistula, etc.);
  • History of brain tumor, severe craniocerebral trauma, encephalitis, meningitis and other central nervous system inflammatory diseases, or other major craniocerebral diseases, any form of invasive brain treatment history and radiotherapy history;
  • Presence of severe or uncontrolled systemic diseases, or vital organ dysfunction that the investigator judges may significantly increase the subject's research risk or affect the completion of follow-up, including but not limited to severe cardiac insufficiency (ejection fraction <50% or NYHA class III-IV cardiac function), severe liver function abnormality (such as ALT or AST > 2 times the upper limit of normal value), severe renal insufficiency (such as serum creatinine > 3 mg/dL), severe or uncontrolled respiratory diseases, severe non-cardiovascular comorbidities with expected survival time <1 year;
  • There is a clear source of cardiogenic embolism, including rheumatic mitral or aortic valve stenosis, prosthetic valve, atrial fibrillation, atrial flutter, sick sinus syndrome, left atrial myxoma, patent foramen ovale, left ventricular mural thrombus, valve vegetation, congestive heart failure, bacterial endocarditis, or other cardiovascular diseases that affect study participation;
  • Uncontrolled severe hypertension, that is, seated systolic blood pressure >180 mmHg and/or diastolic blood pressure >110 mmHg after drug treatment;
  • Severe hemostatic disorder or severe coagulation dysfunction;
  • Contraindications to RIC treatment:

(1) Combined with upper extremity peripheral vascular disease or those judged by the investigator to be unsuitable for upper arm cuff compression, especially vascular lesions that may increase the risk of upper extremity ischemia, including known moderate to severe stenosis or occlusion of the subclavian artery, axillary artery, brachial artery, radial artery or ulnar artery, subclavian steal syndrome, and obvious symptoms of upper extremity ischemia; (2) There are local upper extremity conditions that may affect the safe implementation of RIC, including severe skin or soft tissue infection, skin breakage, unhealed wounds, recent upper extremity trauma or fracture, obvious hematoma, severe edema or lymphedema, arteriovenous fistula or hemodialysis access, PICC or other vascular access not suitable for compression, recent upper extremity deep vein thrombosis or thrombophlebitis, etc.; (3) Known history of allergy to RIC equipment or its constituent materials 8. Patients who refuse follow-up or cannot communicate due to severe mental illness; 9. Unfit for taVNS wearing due to skin breakage, infection, redness and swelling at the wearing site; 10. Pregnant and lying-in women; 11. Participate in other studies at the same period.

Quoted from ClinicalTrials.gov, NCT07889531, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07889531, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07889531